Skip to search formSkip to main contentSkip to account menu

albiglutide

A long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, with antihyperglycemic activity. Albiglutide is composed of a GLP-1 (7-36) dimer… 
National Institutes of Health

Related topics

Related topics

4 relations
0.5 ML albiglutide 60 MG/ML Pen Injector [Tanzeum]Glucagon-Like Peptide 1analogs & derivatives

Narrower (1)

Tanzeum

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
An overview of GLP-1 agonists and recent cardiovascular outcomes trials
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are emerging as an important therapy to consider for patients with type 2… 
Review
2017
Review
2017
The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease
Cardiovascular disease (CVD) remains a leading cause of mortality and morbidity worldwide. Numerous therapies are currently under… 
Highly Cited
2015
Highly Cited
2015
2014 FDA drug approvals
The FDA approved 41 new therapeutics in 2014, but the bumper year fell short of the commercial power of the drugs approved in… 
Review
2015
Review
2015
Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta‐analysis of randomized controlled trials
To assess the efficacy and safety of recently approved once‐weekly glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) in… 
Highly Cited
2014
Highly Cited
2014
Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus…
OBJECTIVE GLP-1 receptor agonists may provide an alternative to prandial insulin for advancing basal insulin therapy. Harmony 6… 
Highly Cited
2014
Highly Cited
2014
HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea
AbstractAims/hypothesisThe aim of this study was to compare the efficacy and safety of once-weekly albiglutide with once-daily… 
Review
2014
Review
2014
Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
Highly Cited
2014
Highly Cited
2014
Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52‐week primary endpoint results from a randomized, double‐blind, placebo‐controlled trial…
To show that albiglutide, a glucagon‐like peptide‐1 receptor agonist, is an effective and generally safe treatment to improve… 
Review
2011
Review
2011
An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists—available efficacy and safety data and perspectives for the future
Incretin‐based therapies, such as the injectable glucagon‐like peptide‐1 (GLP‐1) receptor agonists and orally administered… 
Review
2010
Review
2010
Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes
Importance of the field: Despite the wide array of treatments available, a significant number of patients with type 2 diabetes… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)